Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations

Immunovant CEO Peter Salzmann sold 4,619 shares of common stock on July 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 9, 2024, Peter Salzmann, the CEO of Immunovant, Inc., sold 4,619 shares of Immunovant's common stock.
• The sale was executed at a weighted average price of $28.06 per share, with individual transactions ranging from $27.48 to $28.42.
• This transaction was not discretionary but mandated by Immunovant's policy to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs) through a 'sell to cover' mechanism.
• The shares were sold to cover tax obligations related to the vesting of 8,281 RSUs on July 1, 2024, which were part of a larger grant of 132,500 RSUs awarded on March 19, 2021.
• Following the transaction, Salzmann still beneficially owns 1,032,097 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The Form 4 filing represents a routine transaction to cover tax obligations, which is neither particularly positive nor negative for the company's outlook.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a change in the executive's confidence in the company.

Comparison to Industry Standards

• The 'sell to cover' practice is a standard method for executives to manage tax liabilities associated with equity compensation.
• Many companies, including those in the biotechnology sector like Amgen, Regeneron, and Biogen, have similar policies in place for their executives.

Key Dates